Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS)
BioDrugs - United Kingdom
doi 10.1007/s40259-018-0285-2
Full Text
Open PDFAbstract
Available in full text
Date
June 5, 2018
Authors
Publisher
Springer Science and Business Media LLC